Loading
institutionsInstitution
University of Chicago Medicine Comprehensive Cancer Center
Where Charles Huggins proved hormones drive prostate cancer and Janet Rowley found the chromosome translocations behind leukaemia; strong in tumour immunology today.
Also called: UCCCC
Overview
NCI-designated since 1973 and comprehensive since 2008, the University of Chicago has two foundational cancer discoveries to its name: Charles Huggins's demonstration that castration controls prostate cancer (Nobel Prize 1966), the origin of hormonal therapy, and Janet Rowley's identification of recurrent chromosomal translocations, including the 9;22 translocation that produces BCR-ABL. Today Thomas Gajewski's laboratory defined the T-cell-inflamed ('hot') tumour phenotype and the gut microbiome's influence on checkpoint response; Everett Vokes established chemoradiotherapy for head and neck cancer; Susan Cohn leads international neuroblastoma risk classification. The centre is building a dedicated cancer hospital on its Hyde Park campus.
Location
Chicago, IL, US
Type
cancer center · University of Chicago
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#69 · 45 points (0 Newsweek + 15 NCI + 30 from 15 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to University of Chicago Medicine Comprehensive Cancer Center, including child institutions. 43 works · 2,105 citations · 44% open access · 16% clinical trials · 0% reviews.
Oncology works per year
32022
82023
122024
112025
92026
Most works
- Kunle Odunsi14 works
- Jincong Q. Freeman7 works
- Junko Matsuzaki4 works
- AJ Robert McGray4 works
- Anthony J. Olszanski4 works
- Takemasa Tsuji4 works
- Rita Nanda3 works
- Carly J. Cassara3 works
- Frederick M. Howard3 works
- Igor Puzanov3 works
Most cited
- Tumour immunology and microbiome
- Head and neck cancer
- Neuroblastoma (INRG)
- Leukaemia genetics
Daniel K. Ludwig
Shipping magnate who endowed the Ludwig Institute for Cancer Research in 1971
Cancer research endowmentInstitute buildingCancer immunology
In 1971 he put nearly all of his international holdings into a cancer research institute that carries his name reluctantly; it has since spent more than $1.8 billion of its own money on cancer science.
Hedy L. Kindler
Professor of Medicine and Director of Gastrointestinal Oncology and Mesothelioma Programs, University of Chicago
Pancreatic cancerMesotheliomaTargeted therapy
Senior investigator of POLO and a leader in mesothelioma trials, including the ASCO guidelines for the disease.
Kunle Odunsi
Director
Gynaecologic oncologyCancer immunotherapyCancer vaccines
Gynaecologic oncologist and immunotherapy researcher who directs the University of Chicago Medicine Comprehensive Cancer Center.
Ralph Weichselbaum
Executive Committee Member
Radiation oncologyOligometastasisRadiation and immunotherapy
Radiation oncologist at the University of Chicago known for the oligometastasis concept and for research linking radiation with anti-tumour immunity.
Thomas F. Gajewski
AbbVie Foundation Professor of Cancer Immunotherapy, University of Chicago
Tumour immunologySTING pathwayMicrobiome and immunotherapy
Defined the T-cell-inflamed tumour, discovered STING's role in anti-tumour immunity and showed gut bacteria shape immunotherapy response.
Everett E. Vokes
ASCO President 2021-2022; Chair of Medicine, University of Chicago
Head and neck cancerLung cancerChemoradiation
Head and neck cancer leader who established organ-preserving chemoradiation and led ASCO in 2021-22.
Susan L. Cohn
Professor of Pediatrics, University of Chicago; Children's Oncology Group neuroblastoma leader
NeuroblastomaRisk stratificationPaediatric oncology
Neuroblastoma expert who built the international risk classification used to guide treatment.
Similar pages
- InstitutionFox Chase Cancer Center
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), National Cancer Institute (NIH), Prostate cancer.
- InstitutionLagos University Teaching Hospital
Shares University College Hospital, Ibadan, Prostate cancer.
- InstitutionDavid H. Koch Institute for Integrative Cancer Research at MIT
Shares Daniel K. Ludwig, Ludwig Cancer Research, National Cancer Institute (NIH).
- TermINRG staging and risk groups
Shares Susan L. Cohn, Neuroblastoma (paediatric).
- PersonMatthew R. Smith
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer.
- TrialRTOG 0129 (HPV analysis)
Shares Everett E. Vokes, Head and neck squamous cell carcinoma.
- PersonAndrew J. Armstrong
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer.
- PersonOwen N. Witte
Shares BCR::ABL1 (Philadelphia chromosome), Androgen receptor, Prostate cancer.
cancers
fronts
technologies
targets
institutions
terms
people
Open-source projects
All open source in oncology →Open-source projects that this organisation maintains, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
Deep learning for digital pathology with a focus on reproducible pipelines and uncertainty, from the University of Chicago.
376 starslast push 2026-09-21University of Chicago Medicine Comprehensive Cancer CenterRepositoryPaperThe University of Chicago's open framework for data commons, used by the GDC and many other biomedical commons.